|Datasheet||Specific References||Reviews||Related Products||Protocols|
|0.5 mg/mL of mouse anti-MMP9 monoclonal antibody. Dilute to a working concentration of 2.0 μg/mL in CBS before coating.|
|0.5 mg/mL of biotinylated rabbit anti-MMP9 monoclonal antibody. Dilute to a working concentration of 0.25 μg/mL in detection antibody dilution buffer before use.|
|Each vial contains 70 ng of recombinant MMP9. Reconstitute standard powder with 1mL detection antibody dilution buffer. A seven-point standard curve usi ng 2-fold serial dilutions in sample dilution buffer, and a high standard of 2000 pg/mL is recommended.|
|50 μL of streptavidin conjugated to horseradish-peroxidase. 1:2000 Dilution in detection antibody dilution buffer before use.|
|The minimum detectable dose of human MMP-9 / CLG4B was determined to be approximately 31.25 pg/ml. This is defined as at least three times standard deviations above the mean optical density of 10 replicates of the zero standard.|
The human MMP-9 / CLG4B / MMP9 ELISA Pair Set is for the quantitative determinationof human MMP-9.
This ELISA Pair Set contains the basic components required for the development of sandwich ELISAs.
The Sino Biological ELISA Pair Set is a solid phase sandwich ELISA (Enzyme-Linked Immunosorbent Assay). It utilizes a monoclonal antibody specific for MMP-9 / CLG4B coated on a 96-well plate. Standardsand samples are added to the wells, and any MMP-9 / CLG4B present binds to the immobilizedantibody. The wells are washed and a biotinylated rabbit anti-MMP-9 monoclonal antibody is then added,producing an antibody-antigen-antibody "sandwich". To produces color inproportion to the amount of MMP-9 / CLG4B present in the sample strepavidin-HRP and TMB substratesolution are loaded. The absorbances of the microwell are read at 450 nm.
|Capture Antibody: Aliquot and store at -20℃ to -80℃ for up to 6 months from date of receipt. Avoid repeated freeze-thaw cycles.|
Detection Antibody: Aliquot and store at -20℃ to -80℃ for up to 6 months from date of receipt. Avoid repeated freeze-thaw cycles.
Standard: Store lyophilized Standard at -20℃ to -80℃ for up to 6 months from date of receipt. Aliquot and store the reconstituted Standard at -80℃ for up to 1 month. Avoid repeated freeze-thaw cycles.
Streptavidin-HRP: Store at 4℃ and protect it from prolonged exposure to light. DO NOT FREEZE! It is stable for up to 6 months from date of receipt.
Matrix metalloproteinases (MMPs) are neutral proteinases that are involved in the breakdown and remodeling of the extracellular matrix (ECM) under a variety of physiological and pathological conditions, such as morphogenesis, differentiation, angiogenesis and tissue remodeling, as well as pathological processes including inflammation, arthritis, cardiovascular diseases, pulmonary diseases and tumor invasion. MMP9, also known as 92-kDa gelatinase B/type IV collagenase, is secreted from neutrophils, macrophages, and a number of transformed cells, and is the most complex family member in terms of domain structure and regulation of its activity. It plays an important role in tissue remodelling in normal and pathological inflammatory processes. MMP-9 is a major secretion product of macrophages and a component of cytoplasmic granules of neutrophils, and is particularly important in the pathogenesis of inflammatory, infectious, and neoplastic diseases in many organs including the lung. This enzyme is also secreted by lymphocytes and stromal cells upon stimulation by inflammatory cytokines, or upon delivery of bi-directional activation signals following integrin-mediated cell-cell or cell-extracellular matrix (ECM) contacts. Since the integrity of the tissue architecture is closely dependent of the delicate balance between MMPs and their inhibitors, excessive production of MMP-9 is linked to tissue damage and degenerative inflammatory disorders. As a consequence, regulation of gene transcription and tissue-specific expression of MMP-9 in normal and diseased states are being actively investigated to pave the way for new therapeutic targets. In addition, the dramatic overexpression of MMP-9 in cancer and various inflammatory conditions clearly points to the molecular mechanisms controlling its expression as a potential target for eventual rational therapeutic intervention.